Systems biology and combination therapy in the quest for clinical efficacy
The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Combinatorial control of biological processes, in which redundancy and multifunctionality are the norm, fundamentally limits the therapeutic index that can be achieved by even the most potent and highly selective drugs. Thus, it will almost certainly be necessary to use new 'targeted' pharmaceuticals in combinations. Multicomponent drugs are standard in cytotoxic chemotherapy, but their development has required arduous empirical testing. However, experimentally validated numerical models should greatly aid in the formulation of new combination therapies, particularly those tailored to the needs of specific patients. This perspective focuses on opportunities and challenges inherent in the application of mathematical modeling and systems approaches to pharmacology, specifically with respect to the idea of achieving combinatorial selectivity through use of multicomponent drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Overall, these examples demonstrate the potential use of mechanistic and data driven modelling in dose selection, studies of drug-drug interaction, and identification of the most efficient therapies [338].”
From Cardiovascular disease models: A game changing paradigm in drug discovery and screening (2019) · cites this paper as [338]
In the citing paper
“Accurate predictions of combination treatments from single treatment data would allow a cost-effective pre-selection of promising drug candidates for experimental follow-up, which is highly relevant for modern personalized medicine (Fitzgerald et al., 2006).”
From Efficient Parameter Estimation Enables the Prediction of Drug Response Using a Mechanistic Pan-Cancer Pathway Model (2018) · cites this paper as Fitzgerald et al., 2006
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
Arzneimittelforschung: Eine Zukunftsoption für Ärzte?
Bethke, T. D. (2012) · Der Pneumologe · doi:10.1007/s10405-012-0601-3 · Cited by 3,261
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561 · cited 1×
“However, growth of cells in the presence of IGF-1 was found to be unaffected when mTOR was inhibited with a rapamycin analog; instead, activity of the upstream regulator Akt increase”
BackgroundRobustness in the Strategy of Scientific Model Building
Box, G. E. P. (1979) · Robustness in Statistics · doi:10.1016/b978-0-12-438150-6.50018-2 · Cited by 1,562
Enzyme and metabolic inhibitors
Webb, J. L. (1963) · Academic Press eBooks · doi:10.5962/bhl.title.7320 · Cited by 1,514
The search for synergy: a critical review from a response surface perspective.
Greco, W. R., Bravo, G., & Parsons, J. C. (1995) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06847-4 · Cited by 1,434
Berenbaum, M. C. (1989) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00026-2 · Cited by 1,414
Cell-signalling dynamics in time and space
Kholodenko, B. N. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1838 · Cited by 1,347 · cited 1×
“However, large models with multiple signaling circuits raise new conceptual issues, such as how best to represent the partitioning of shared components (for example, Ras, MAP kinases and others) among potentially competing pathway”
BackgroundThe tor pathway: a target for cancer therapy
Bjornsti, M.-A., & Houghton, P. J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1362 · Cited by 1,314 · cited 1×
“Inhibition of mTOR is promising as an anticancer strategy, as many proteins lying upstream and downstream of mTOR are deregulated in a human cance”
Background
Cited by
Items 101–200 of 570
Systems pharmacology and genome medicine: a future perspective
Wist, A. D., Berger, S., & Iyengar, R. (2009) · Genome Medicine · doi:10.1186/gm11 · Cited by 95
“In proactive approaches, network analysis [42] or computational modeling [69] can”
MethodASDCD: Antifungal Synergistic Drug Combination Database
Chen, X., Ren, B., Chen, M., Liu, M.-X., Ren, W., Wang, Q.-X., Zhang, L.-X., & Yan, G.-Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086499 · Cited by 84
“Also, the development of drug resistance can be slowed down by the use of drug combinations because biological systems are less able to compensate for the simultaneous action of two or more drugs [1,2,4–7].”
BackgroundBioinformatics and variability in drug response: a protein structural perspective
Lahti, J. L., Tang, G. W., Capriotti, E., Liu, T., & Altman, R. B. (2012) · Journal of The Royal Society Interface · doi:10.1098/rsif.2011.0843 · Cited by 89
Miller, M. L., Molinelli, E. J., Nair, J. S., Sheikh, T., Samy, R., Jing, X., He, Q., Korkut, A., Crago, A. M., Singer, S., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004014 · Cited by 86
“The CI score is well suited for estimating effects of drug combinations as it is based on the concept of dosesubstitution and can handle cases where the two drugs are the same, act on the same target, or act on targets converging in a common pathway (15).”
Advanced Systems Biology Methods in Drug Discovery and Translational Biomedicine
Zou, J., Zheng, M.-W., Li, G., & Su, Z. (2013) · BioMed Research International · doi:10.1155/2013/742835 · Cited by 90
Szlachta, K. A., Kuscu, C., Tufan, T., Adair, S. J., Shang, S., Michaels, A. D., Mullen, M. G., Fischer, N. L., Yang, J., Liu, L., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06676-2 · Cited by 93
Systems medicine: evolution of systems biology from bench to bedside
Wang, R., Maron, B. A., & Loscalzo, J. (2015) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1297 · Cited by 88
“97 , 98 However, experimental screening of drug combinations is very costly and often only identifies a small number of synergistic combinations owing to the large search space.”
BackgroundMulti-scale Modeling in Clinical Oncology: Opportunities and Barriers to Success
Yankeelov, T. E., An, G., Saut, O., Luebeck, E. G., Popel, A. S., Ribba, B., Vicini, P., Zhou, X., Weis, J. A., Ye, K., et al. (2016) · Annals of Biomedical Engineering · doi:10.1007/s10439-016-1691-6 · Cited by 80
Mitochondrial targeted strategies and their application for cancer and other diseases treatment
Li, Q., & Huang, Y. (2020) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-020-00481-0 · Cited by 86
“Finally, since the onset of diseases is a complex physiological network, combination therapy emerges to be the current trend of disease treatment in clinical (Fitzgerald et al. 2006; Ghosh et al. 2018).”
BackgroundChemogenomic profiling predicts antifungal synergies
Jansen, G., Lee, A. Y., Epp, E., Fredette, A., Surprenant, J., Harcus, D., Scott, M., Tan, E., Nishimura, T., Whiteway, M., et al. (2009) · Molecular Systems Biology · doi:10.1038/msb.2009.95 · Cited by 80
“In particular, synergies between the constituent compounds can provide broader pharmacological windows and reduced toxicity”
BackgroundA systems biology approach to identify effective cocktail drugs
Wu, Z., Zhao, X., & Chen, L. (2010) · BMC Systems Biology · doi:10.1186/1752-0509-4-s2-s7 · Cited by 85
“In this model, the combined effect of two inhibitors is predicted as the multiplication of single inhibitors ’ s effect and represented as the union of two probabilistically independent events [6].”
BackgroundInfluentialReynolds, D., Huesemann, M. H., Edmundson, S. J., Sims, A. M., Hurst, B. L., Cady, S. L., Beirne, N., Freeman, J., Berger, A., & Gao, S. (2021) · Algal Research · doi:10.1016/j.algal.2021.102331 · Cited by 82
“An unrefined sample containing a multitude of compounds may thus improve therapeutic efficacy by eliminating the effects of harmful pathogens at various stages of the infection cycle, reducing the likelihood for developing harmful mutations, and decreasing the cost of treatment preparation [32,77].”
BackgroundDrug-Drug Interactions and Synergy: From Pharmacological Models to Clinical Application
Calzetta, L., Page, C. P., Matera, M. G., Cazzola, M., & Rogliani, P. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.124.000951 · Cited by 82
Croft, D. R., Crighton, D., Samuel, M. S., Lourenco, F. C., Munro, J., Wood, J., Bensaad, K., Vousden, K. H., Sansom, O. J., Ryan, K. M., et al. (2011) · Cell Research · doi:10.1038/cr.2010.154 · Cited by 75
“Since administration of LIMK inhibitors may be useful as an anti-metastatic strategy [10], their additional possible use in combination therapy as a chemosensitizing agent [37] increases their potential therapeutic value.”
Benamar, M., Guessous, F., Du, K., Corbett, P., Obeid, J., Gioeli, D., Slingluff, C. L., & Abbas, T. (2016) · eBioMedicine · doi:10.1016/j.ebiom.2016.06.023 · Cited by 77
“Synergy was determined using the Bliss model of independence (Bliss, 1939; Fitzgerald et al., 2006).”
MethodPredict effective drug combination by deep belief network and ontology fingerprints
Chen, G., Tsoi, A., Xu, H., & Zheng, W. J. (2018) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2018.07.024 · Cited by 74
Using Combination Therapy to Thwart Drug Resistance
Hill, J. A., & Cowen, L. E. (2015) · Future Microbiology · doi:10.2217/fmb.15.68 · Cited by 75
Towards Structural Systems Pharmacology to Study Complex Diseases and Personalized Medicine
Xie, L., Ge, X., Tan, H., Xie, L., Zhang, Y., Hart, T. D., Yang, X., & Bourne, P. E. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003554 · Cited by 81
“Due to the robust nature of biological systems, drug combinations are often necessary and proven to be successful in treating complex diseases and combating drug resistance [164–165].”
BackgroundVanderdys, V., Allak, A., Guessous, F., Benamar, M., Read, P. W., Jameson, M. J., & Abbas, T. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0083 · Cited by 81
“Synergy was determined using the Bliss model of independence (37, 38).”
MethodSystems Biology Brings New Dimensions for Structure-Based Drug Design
Pei, J., Yin, N., Ma, X., & Lai, L. (2014) · Journal of the American Chemical Society · doi:10.1021/ja504810z · Cited by 73
Yan, H., Zhang, B., Li, S., & Zhao, Q. (2010) · BMC Systems Biology · doi:10.1186/1752-0509-4-50 · Cited by 73
“From the results in [1] the influence of feedback on combination effects is verified to have nonnegative impact under the condition 1) in Lemma 2.”
BackgroundMethodResultInfluentialFrequently asked questions in drug combinations and the mass-action law-based answers
Chou, T. (2014) · Synergy · doi:10.1016/j.synres.2014.07.003 · Cited by 79
Schoeberl, B., Kudla, A. J., Masson, K., Kalra, A. V., Curley, M., Finn, G. J., Pace, E. A., Harms, B. D., Kim, J., Kearns, J. D., et al. (2017) · npj Systems Biology and Applications · doi:10.1038/npjsba.2016.34 · Cited by 74
“In addition to empirically discovering drugs like paclitaxel that combine well with seribantumab, we also used our computational models to predict which targeted agents would mechanistically synergize with seribantumab to inhibit p-Akt.(36) On the basis of dynamic simulations, the combination of an anti-EGFR inhibitor…”
MethodSelf-citationPrediction of ultra-high-order antibiotic combinations based on pairwise interactions
Katzir, I., Cokol, M., Aldridge, B. B., & Alon, U. S. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006774 · Cited by 77
Lipid metabolism as a target for cancer drug resistance: progress and prospects
Wang, Z., Wang, Y., Li, Z., Xue, W., Hu, S., & Kong, X. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1274335 · Cited by 79
“Studies have indicated that the utilization of combination therapies targeting multiple pathways may effectively delay the development of therapeutic resistance (Fitzgerald et al., 2006).”
Chakrabarti, S., & Michor, F. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2871 · Cited by 72
“Although the importance of drug interactions has been well established in classical methods of drug development and dosing (42), very few evolutionary models have explored its role in shaping the dynamics of cancer.”
A systems approach to clinical oncology uses deep phenotyping to deliver personalized care
Yurkovich, J. T., Tian, Q., Price, N. D., & Hood, L. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0273-6 · Cited by 79
Additivity of inhibitory effects in multidrug combinations
Russ, D., & Kishony, R. (2018) · Nature Microbiology · doi:10.1038/s41564-018-0252-1 · Cited by 71
Mizukawa, B., Wei, J., Shrestha, M., Wunderlich, M., Chou, F.-S., Griesinger, A., Harris, C. E., Kumar, A. R., Zheng, Y., Williams, D. A., et al. (2011) · Blood · doi:10.1182/blood-2011-04-351817 · Cited by 70
Wu, C., Karioti, A., Rohr, D., Bilia, A. R., & Efferth, T. (2016) · Food Chemistry · doi:10.1016/j.foodchem.2016.01.054 · Cited by 69
Gag-Pol Processing during HIV-1 Virion Maturation: A Systems Biology Approach
Könnyű, B., Sadiq, S. K., Turányi, T., Hírmondó, R., Müller, B., Kräusslich, H.-G., Coveney, P. V., & Müller, V. (2013) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003103 · Cited by 58
“Systems modelling has been used to identify and characterize synergistic drug interactions that can enhance the effect of drugs [29,30].”
BackgroundBiochemical network-based drug-target prediction
Klipp, E., Wade, R. C., & Kummer, U. (2010) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2010.05.004 · Cited by 71
Efficient discovery of anti-inflammatory small-molecule combinations using evolutionary computing
Small, B. G., McColl, B. W., Allmendinger, R., Pahle, J., López‐Castejón, G., Rothwell, N. J., Knowles, J. D., Mendes, P., Brough, D., & Kell, D. B. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.689 · Cited by 78
Gioeli, D. G., Wunderlich, W., Sebolt, J. S., Bekiranov, S., Wulfkuhle, J. D., Petricoin, E. F., Conaway, M. C., & Weber, M. J. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1033 · Cited by 71
“Bliss independence was determined by the equation: Bliss independent effect 1⁄4 1 (effect drug 1 effect drug 2) for specific dose of each drug (17, 18).”
MethodYeo, K. L., Chen, Y., Xu, H. Y., Dong, H., Wang, Q.-Y., Yokokawa, F., & Shi, P. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04779-14 · Cited by 68
“Firstly, synergy 284 between two drugs would allow achieving efficacy at lower doses, leading to increased 285 therapeutic window of potentially toxic compounds (45).”
BackgroundNetwork based elucidation of drug response: from modulators to targets
Iorio, F., Saez-Rodriguez, J., & Bernardo, D. D. (2013) · BMC Systems Biology · doi:10.1186/1752-0509-7-139 · Cited by 64
“Furthermore, they can include non-linear effects, allowing to study complex behaviours such as the synergistic combinations of drugs [24,25].”
BackgroundPredictive model identifies key network regulators of cardiomyocyte mechano-signaling
Tan, P. M., Buchholz, K. S., Omens, J. H., McCulloch, A. D., & Saucerman, J. J. (2017) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005854 · Cited by 66
Combined c-Met/Trk Inhibition Overcomes Resistance to CDK4/6 Inhibitors in Glioblastoma
Olmez, I., Zhang, Y., Manigat, L. C., Benamar, M., Brenneman, B. R., Nakano, I., Godlewski, J. A., Bronisz, A., Lee, J., Abbas, T., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3124 · Cited by 68
“The Bliss difference was calculated as described previously (22).”
MethodKong, L., Wang, X., Zhang, K., Yuan, W., Yang, Q., Fan, J., Wang, P., & Liu, Q. (2015) · PLoS ONE · doi:10.1371/journal.pone.0137888 · Cited by 64
“Recently, combination or multi-component (rather than single-agent) therapy, in which two or more kinds of drugs are used simultaneously, is a proved treatment for cancer [6,7].”
BackgroundGeretti, E., Leonard, S. C., Dumont, N., Lee, H., Zheng, J., De Souza, R., Gaddy, D. F., Espelin, C. W., Jaffray, D. A., Moyo, V., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0314 · Cited by 61
Self-citationTekin, E., Beppler, C., White, C., Mao, Z., Savage, V. M., & Yeh, P. J. (2016) · Journal of The Royal Society Interface · doi:10.1098/rsif.2016.0332 · Cited by 71
“Multi-drug treatments are an important tool [1–5], in particular, for combatting bacteria that are highly resistant to the individual use of traditional antibiotics [6–11].”
BackgroundDrug Combinations: Mathematical Modeling and Networking Methods
Vakil, V., & Trappe, W. K. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11050208 · Cited by 68
“Drug combinations in signaling networks according to [38]: (a) Inhibition at two parallel pathways converging to a single target protein; (b) Inhibition at the same site of action; (c) Inhibition at different sites of action; (d) Inhibition at different levels; (e) Inhibition at different levels with a negative feedba…”
BackgroundMethodInfluentialA Systematic Review of Applications of Machine Learning in Cancer Prediction and Diagnosis
Sharma, A., & Rani, R. (2021) · Archives of Computational Methods in Engineering · doi:10.1007/s11831-021-09556-z · Cited by 67
Li, W., Luo, T., Yang, Y., Tan, X., & Liu, L. (2015) · Langmuir · doi:10.1021/la504796v · Cited by 60
Zhai, Q., & Li, J. (2019) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2019.01.008 · Cited by 60
“Combinations of medicines can substantially reduce the probability of evolving drug resistance and improve efficacy [10].”
BackgroundJi, H.-F., Kong, D.-X., Shen, L., Chen, L.-L., Ma, B.-G., & Zhang, H.-Y. (2007) · Genome Biology · doi:10.1186/gb-2007-8-8-r176 · Cited by 59
“One is called the multicomponent therapeutic strategy, which incorporates two or more active ingredients in one drug [86-89], as was applied in some traditional medicines (in China and many other countries) and in recently developed drug cocktails.”
BackgroundLiu, Y.-T., Peng, J.-B., Jia, H., Cai, D.-Y., Zhang, H., Yu, C., & Zou, Z. (2014) · Phytomedicine · doi:10.1016/j.phymed.2014.05.009 · Cited by 59
Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic
Kearns, J. D., Bukhalid, R., Sevecka, M., Tan, G., Gerami-Moayed, N., Werner, S. L., Kohli, N., Burenkova, O., Sloss, C. M., King, A. M., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0772 · Cited by 56
“Development of MM-151: an oligoclonal combination of a-EGFR antibodies Inspired by a systems biology analysis from our group that described synergistic inhibition of a cell surface receptor tyrosine kinase by a combination of two or more targeted agents (50), we # ligands 0 1 2 3 4 5 Colorectal (n = 333) Head & neck (…”
BackgroundSelf-citationModular pharmacology: the next paradigm in drug discovery
Wang, Z., Liu, J., Yu, Y., Chen, Y., & Wang, Y. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.692673 · Cited by 59
“achieving combinatorial selectivity through the use of multicomponent drugs [9], have required drugs of higher order or adequate modular structure.”
BackgroundSun, X., Su, J., Bao, J., Peng, T., Zhang, L., Zhang, Y., Yang, Y., & Zhou, X. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.07.041 · Cited by 59
“And then, we adopted the Loewe additivity [40,41] and Bliss independence [41e43] to evaluate and examine whether the combination effect of Wnt and BMP2 is synergy or not.”
MethodCai, H., Kapoor, A., He, R., Venkatadri, R., Forman, M., Posner, G. H., & Arav‐Boger, R. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01972-13 · Cited by 59
“Several methods have been used to calculate the expected doseresponse relationship for combination therapy compared to that for monotherapy, of which the Loewe additivity (isobologram method) and Bliss independence methods have been commonly used (41).”
MethodUnconventional screening approaches for antibiotic discovery
Farha, M. A., & Brown, E. D. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12803 · Cited by 60
Uncovering Scaling Laws to Infer Multidrug Response of Resistant Microbes and Cancer Cells
Wood, K. B., Wood, K. C., Nishida, S., & Cluzel, P. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.02.007 · Cited by 61
“Response surfaces are commonly used for quantifying and classifying the interactions between two drugs based on measurements of cell proliferation (Fitzgerald et al., 2006; Greco et al., 1995; Lehar et al., 2008; Lehar et al., 2007).”
InfluentialZhu, W., Mazzanti, A., Voelker, T. L., Hou, P., Moreno, J. D., Angsutararux, P., Naegle, K. M., Priori, S. G., & Silva, J. R. (2018) · Circulation Research · doi:10.1161/circresaha.118.314050 · Cited by 57
Wang, J., Zhang, H., Xiao, X., Liang, D., Liang, X., Mi, L., Wang, J., & Liu, J. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.03.001 · Cited by 56
Stratification and prediction of drug synergy based on target functional similarity
Yang, M., Jaaks, P., Dry, J. R., Garnett, M. J., Menden, M. P., & Sáez-Rodríguez, J. (2020) · npj Systems Biology and Applications · doi:10.1038/s41540-020-0136-x · Cited by 62
Systems pharmacology, pharmacogenetics, and clinical trial design in network medicine
Antman, E. M., Weiss, S. T., & Loscalzo, J. (2012) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1173 · Cited by 54
Computing Combinatorial Intervention Strategies and Failure Modes in Signaling Networks
Samaga, R., von Kamp, A., & Klamt, S. (2010) · Journal of Computational Biology · doi:10.1089/cmb.2009.0121 · Cited by 53
“Re-dundancy Re-dundancy requires that several routes must be targeted whereas multifunctionality implies that intervening at central players often causes unintended side effects so that one has to search for alternative and possibly more distributed points of interventions (Fitzgerald et al., 2006).”
Wali, V. B., Langdon, C. G., Held, M. A., Platt, J. T., Patwardhan, G. A., Safonov, A. M., Aktaş, B., Pusztai, L., Stern, D. F., & Hatzis, C. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1901 · Cited by 58
“We used the Bliss model of synergy (19,20) to assess superadditivity.”
MethodMechanistic model of MAPK signaling reveals how allostery and rewiring contribute to drug resistance
Fröhlich, F., Gerosa, L., Muhlich, J. L., & Sorger, P. K. (2023) · Molecular Systems Biology · doi:10.15252/msb.202210988 · Cited by 55
“…way to investigate mechanisms of drug interaction (Fröhlich et al, 2018; Yuan et al, 2020) and it has been postulated, on theoretical grounds, that inhibition of enzymes acting sequentially in a pathway is a means to achieve synergistic drug interaction (Yin et al, 2014; Fitzgerald et al, 2006).”
BackgroundSelf-citationFaversani, A., Vaira, V., Moro, G. P., Tosi, D., Lopergolo, A., Schultz, D. C., Rivadeneira, D., Altieri, D. C., & Bosari, S. (2014) · Breast Cancer Research · doi:10.1186/bcr3666 · Cited by 51
The impact of quasispecies dynamics on the use of therapeutics
Perales, C., Iranzo, J., Manrubia, S. C., & Domingo, E. (2012) · Trends in Microbiology · doi:10.1016/j.tim.2012.08.010 · Cited by 55
Sun, X., Bao, J., Nelson, K. C., Li, K. C., Kulik, G., & Zhou, X. (2013) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003358 · Cited by 55
“Another quantification method for combination therapies is Bliss independence [27,29].”
Liu, K., Zheng, D., Zhao, J., Tao, Y., Wang, Y., He, J., Lei, J., & Xi, X. (2018) · Journal of Materials Chemistry B · doi:10.1039/c8tb01295d · Cited by 51
Behzadi, S., Gallei, M., Elbert, J., Appold, M., Glaßer, G., Landfester, K., & Crespy, D. (2016) · Polymer Chemistry · doi:10.1039/c6py00344c · Cited by 53
Ebrahimkhani, M. R., Young, C. L., Lauffenburger, D. A., Griffith, L. G., & Borenstein, J. T. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.04.017 · Cited by 45
“Dynamic models promote drug discovery efforts [82,97], as well as quantitative pharmacology and drug development [98,99].”
KGANSynergy: knowledge graph attention network for drug synergy prediction
Zhang, G., Gao, Z., Yan, C., Wang, J., Liang, W., Luo, J., & Luo, H. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad167 · Cited by 53
Xiang, L., Jiang, P., Zhan, C., Chen, Z., Liu, X., Huang, X., Wang, S., Hu, Y., Zhang, W., & Liu, R. (2012) · Molecular BioSystems · doi:10.1039/c2mb25172h · Cited by 50
Drug interaction: focusing on response surface models
Lee, S.-I. (2010) · Korean Journal of Anesthesiology · doi:10.4097/kjae.2010.58.5.421 · Cited by 43
“The Bliss independence and Loewe additivity models are the two most cited reference models for determining drug interaction [9,10,27,28].”
Gazi, M., Moharram, S. A., Marhäll, A., & Kazi, J. U. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.01.035 · Cited by 47
PyBioNetFit and the Biological Property Specification Language
Mitra, E. D., Suderman, R., Colvin, J., Ionkov, A., Hu, A., Sauro, H. M., Posner, R. G., & Hlavacek, W. S. (2019) · iScience · doi:10.1016/j.isci.2019.08.045 · Cited by 46
“In particular, optimization of therapeutic treatments has been a long-standing goal in the systems biology field [89].”
BackgroundPlace, R. F., Krieger, C. C., Neumann, S., & Gershengorn, M. C. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13693 · Cited by 47
“For instance, drugs inhibiting different parts of the same linear pathway typically act according to Loewe additivity (Fitzgerald et al., 2006).”
BackgroundPluskal, T., & Weng, J. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00411g · Cited by 49
Wu, C., Cui, M., Cai, L., Chen, C., Zhu, X., Wu, Y., Liu, J., Wang, H., & Zhang, Y. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c01138 · Cited by 47
Wood, K. B., & Cluzel, P. (2012) · BMC Systems Biology · doi:10.1186/1752-0509-6-48 · Cited by 51
“phenomenological null model for the physiological effects of non-interacting drugs on cell proliferation or growth [10,14,28-30].”
A Systems Perspective of Ras Signaling in Cancer
Stites, E. C., & Ravichandran, K. S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2753 · Cited by 43
Multi-scale agent-based modeling on melanoma and its related angiogenesis analysis
Wang, J., Zhang, L., Jing, C., Ye, G., Wu, H., Miao, H., Wu, Y., & Zhou, X. (2013) · Theoretical Biology and Medical Modelling · doi:10.1186/1742-4682-10-41 · Cited by 45
“Dramatic synergistic effects of the Dox and Sunitinib were observed if the total elimination of melanoma cells (E100 at time point 400 hr) was used as the criterion for Loewe combination index [37-39].”
BackgroundMethodAxelrod, M. J., Gordon, V. L., Conaway, M. R., Tarcsafalvi, A., Neitzke, D. J., Gioeli, D. G., & Weber, M. J. (2013) · Oncotarget · doi:10.18632/oncotarget.938 · Cited by 49
“Synergy was assessed by comparing observed values and values that would be predicted by Bliss-independence [30,31] and by testing for interactions terms in the two-way ANOVA.”
MethodWang, J., Guo, Z., Fu, Y., Wu, Z., Huang, C., Zheng, C., Shar, P. A., Wang, Z., Xiao, W., & Wang, Y. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbw018 · Cited by 49
Hosseini, S., & Zhou, X. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac588 · Cited by 48
Synergistic effects of β-aescin and 5-fluorouracil in human hepatocellular carcinoma SMMC-7721 cells
Ming, Z. J., Hu, Y., Qiu, Y., Cao, L., & Zhang, X. (2010) · Phytomedicine · doi:10.1016/j.phymed.2009.12.009 · Cited by 43
De, K., Li, X., Tang, G.-Y., & Zhang, H. (2007) · ChemMedChem · doi:10.1002/cmdc.200700291 · Cited by 45
Kobayashi, T., Koizumi, Y., Takeuchi, J. S., Misawa, N., Kimura, Y., Morita, S., Aihara, K., Koyanagi, Y., Iwami, S., & Sato, K. (2014) · Journal of Virology · doi:10.1128/jvi.00062-14 · Cited by 44
“Here, we estimated the combination of each antiviral effect by Bliss independence, which is a major index for the evaluation of drug combination effects (41, 42).”
BackgroundModeling Tumor Clonal Evolution for Drug Combinations Design
Zhao, B., Hemann, M. T., & Lauffenburger, D. A. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.02.001 · Cited by 48
“Several excellent reviews on tumor heterogeneity [1–4], drug resistance [5–8], drug combinations design [9–12] are available, and we therefore aim here to integrate germane quantitative approaches, with a focus on recent developments and applications to understanding and predicting therapeutic effects.”
BackgroundWitkin, J. M., Mitchell, S. N., Wafford, K. A., Carter, G., Gilmour, G., Li, J., Eastwood, B. J., Overshiner, C. D., Li, X., Rorick‐Kehn, L. M., et al. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.238121 · Cited by 42
Synergistic Inhibition of Glycinergic Transmission In Vitro and In Vivo by Flavonoids and Strychnine
Raafat, K. M., Breitinger, U., Mahran, L., Ayoub, N., & Breitinger, H. (2010) · Toxicological Sciences · doi:10.1093/toxsci/kfq245 · Cited by 43
“…genistein and quercetin both target the same site on the GlyR, their coapplication would be an example of dose additivity or Loewe additivity (Berenbaum, 1989; Loewe, 1953), with binding of genistein or quercetin being mutually exclusive (Fitzgerald et al., 2006; Tallarida, 1992, 2001).”
BackgroundMethodInfluentialPrediction of drug cocktail effects when the number of measurements is limited
Zimmer, A., Tendler, A., Katzir, I., Mayo, A., & Alon, U. S. (2017) · PLoS Biology · doi:10.1371/journal.pbio.2002518 · Cited by 43
Kee, T. W., Weiyan, C., Blasiak, A., Wang, P., Chong, J. K., Chen, J., Yeo, B. T. T., Ho, D., & Asplund, C. L. (2019) · Advanced Therapeutics · doi:10.1002/adtp.201900023 · Cited by 45
McKinstry-Wu, A. R., Wasilczuk, A. Z., Harrison, B. A., Bedell, V. M., Sridharan, M. J., Breig, J. J., Pack, M. A., Kelz, M. B., & Proekt, A. (2019) · eLife · doi:10.7554/elife.50143 · Cited by 43
“One of the great promises of personalized medicine is the delivery of a maximally efficacious and minimally harmful dose of appropriate medication to every patient (Fitzgerald et al., 2006).”
BackgroundDrug Combination Modeling: Methods and Applications in Drug Development
Pearson, R. A., Wicha, S. G., & Okour, M. (2022) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2128 · Cited by 39
“To illustrate the Loewe additivity model concepts with an example, take 2 drugs in combination, drug A and drug B; assume each (1) have a characterized concentration-effect curve, (2) are in a constant potency ratio (same curve shape except different EC50 value), and (3) reach a mutual Emax.”
MethodLin, Y., Richards, F. M., Krippendorff, B.-F., Bramhall, J. L., Harrington, J., Bapiro, T. E., Robertson, A. A. B., Zheleva, D. I., & Jodrell, D. I. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.450 · Cited by 39
“Paclitaxel and CYC3 were dissolved in dimethylsulphoxide (DMSO) and then diluted in culture medium to a final concentration of 0.2% DMSO.”
MethodInfluentialAnti-Tumour Efficacy of Capecitabine in a Genetically Engineered Mouse Model of Pancreatic Cancer
Courtin, A., Richards, F. M., Bapiro, T. E., Bramhall, J. L., Neeße, A., Cook, N., Krippendorff, B., Tuveson, D. A., & Jodrell, D. I. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067330 · Cited by 39
“The effect of the combination was evaluated using the Bliss Independance model [21,22] according to the protocol we have described previously [23].”
MethodOricchio, E., Ciriello, G., Jiang, M., Boice, M., Schatz, J. H., Heguy, A., Viale, A. J., de Stanchina, E., Teruya‐Feldstein, J., Bouska, A. C., et al. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20132120 · Cited by 40
“…models; notably, all FL cell lines CDK4/6 and is currently in clinical trials against several cancers, including mantle cell lymphoma, but patients with indolent FL have been specifically excluded (e.g., http://clinicaltrials.gov/ show/NCT01111188; Fry et al., 2004; Flaherty et al., 2012).”
BackgroundNetworks from drug–drug surfaces
Yeh, P. J., & Kishony, R. (2007) · Molecular Systems Biology · doi:10.1038/msb4100133 · Cited by 42
“Multi-drug combinations are vital in modern medicine (Keith et al , 2005; Fitzgerald et al , 2006).”
Banala, V. T., Sharma, S., Barnwal, P., Urandur, S., Shukla, R. P., Ahmad, N., Mittapelly, N., Pandey, G., Dwivedi, M., Kalleti, N., et al. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201800300 · Cited by 40
Koizumi, Y., & Iwami, S. (2014) · Theoretical Biology and Medical Modelling · doi:10.1186/1742-4682-11-41 · Cited by 40
“Research on biological network systems, as well as the biochemical characteristics of drugs, has also unraveled the mechanisms by which drug combinations produce synergistic effects (reviewed in [41,43-45]).”
BackgroundSalvador‐Reyes, L. A., Engene, N., Paul, V. J., & Luesch, H. (2015) · Journal of Natural Products · doi:10.1021/np500931q · Cited by 38
Diaz, J. E. L., Ahsen, M. E., Schaffter, T., Chen, X., Realubit, R. B., Karan, C., Califano, A., Losic, B., & Stolovitzky, G. A. (2020) · eLife · doi:10.7554/elife.52707 · Cited by 40
Neighbor communities in drug combination networks characterize synergistic effect
Zou, J., Ji, P., Zhao, Y., Li, L., Wei, Y.-Q., Chen, Y., & Yang, S. (2012) · Molecular BioSystems · doi:10.1039/c2mb25267h · Cited by 41
Looking beyond the cancer cell for effective drug combinations
Dry, J. R., Yang, M., & Sáez-Rodríguez, J. (2016) · Genome Medicine · doi:10.1186/s13073-016-0379-8 · Cited by 41
Metadata
- Authors
- Fitzgerald, J. B., Schoeberl, B., Nielsen, U. B., & Sorger, P. K.
- Affiliations
- Merrimack Pharmaceuticals (United States) (US)
- Harvard University (US)
- Corresponding author
- Sorger, Peter K
- Venue
- Nature Chemical Biology
- Published
- 2006-08-18
- Volume
- 2
- Issue
- 9
- Pages
- 458-466
- ISSN
- 1552-4450 (ISSN-L)
- 1552-4469
- OpenAlex
- W1994663540
- Cited by
- 570
- References
- 68
- Citations by year
- 2026: 14 · 2025: 15 · 2024: 23 · 2023: 28 · 2022: 30 · 2021: 23 · 2020: 32 · 2019: 36 · 2018: 39 · 2017: 40 · 2016: 45 · 2015: 41 · 2014: 45 · 2013: 34 · 2012: 36
- FWCI
- 12.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Chemical Biology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p50gm068762-10)
- National Institute of General Medical Sciences (GM 68762)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene Regulatory Network Analysis
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Keywords
- combination therapy, systems biology, targeted therapy, therapeutic index, personalized medicine, cytotoxic chemotherapy
- MeSH terms
- Drug Therapy, Combination, Models, Biological, Feedback, Physiological, Systems Biology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.